Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 08
Swedish (OMX) Pharma Industry Analysis
UpdatedMay 12, 2024
DataAggregated Company Financials
Companies33
- 7D7.7%
- 3M1.3%
- 1Y57.4%
- YTDn/a
Over the last 7 days, the Pharma industry has risen 7.7%, driven by gains from Camurus of 13%. In the last 12 months, the industry was up 57%. Earnings are forecast to grow by 52% annually.
Industry Valuation and Performance
Has the Swedish Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 12 May 2024 | kr53.2b | kr6.4b | -kr803,399,924.35 | 72.1x | -66.2x | 8.4x |
| Tue, 09 Apr 2024 | kr52.7b | kr6.2b | -kr1,038,113,591.50 | 78.9x | -50.7x | 8.4x |
| Thu, 07 Mar 2024 | kr49.0b | kr6.2b | -kr1,038,058,287.90 | 81x | -47.2x | 7.9x |
| Sat, 03 Feb 2024 | kr68.3b | kr9.5b | -kr1,181,825,181.00 | 64.2x | -57.8x | 7.2x |
| Mon, 01 Jan 2024 | kr68.6b | kr9.4b | -kr1,184,253,680.00 | 65.1x | -57.9x | 7.3x |
| Wed, 29 Nov 2023 | kr61.4b | kr9.5b | -kr1,175,137,221.00 | 54.6x | -52.3x | 6.5x |
| Fri, 27 Oct 2023 | kr51.9b | kr9.3b | -kr1,142,706,422.00 | 102.3x | -45.4x | 5.6x |
| Sun, 24 Sep 2023 | kr52.2b | kr9.2b | -kr1,177,363,371.00 | 134.7x | -44.3x | 5.7x |
| Tue, 22 Aug 2023 | kr50.6b | kr9.1b | -kr1,308,374,410.00 | 83.9x | -38.7x | 5.5x |
| Thu, 20 Jul 2023 | kr50.7b | kr8.8b | -kr1,370,027,017.00 | 79.1x | -37x | 5.8x |
| Sat, 17 Jun 2023 | kr48.3b | kr8.4b | -kr1,728,189,951.00 | 78.5x | -28x | 5.8x |
| Mon, 15 May 2023 | kr49.7b | kr8.2b | -kr1,774,329,569.00 | 90.8x | -28x | 6.1x |
| Wed, 12 Apr 2023 | kr45.6b | kr8.0b | -kr1,793,930,547.00 | 92.1x | -25.4x | 5.7x |
| Fri, 10 Mar 2023 | kr44.4b | kr8.0b | -kr1,791,672,250.00 | 86.7x | -24.8x | 5.6x |
| Sun, 05 Feb 2023 | kr47.6b | kr7.3b | -kr1,966,344,976.00 | 276.3x | -24.2x | 6.5x |
| Tue, 03 Jan 2023 | kr48.5b | kr7.3b | -kr1,910,710,666.00 | 283.7x | -25.4x | 6.6x |
| Thu, 01 Dec 2022 | kr49.8b | kr7.3b | -kr1,876,674,032.00 | 307x | -26.5x | 6.8x |
| Sat, 29 Oct 2022 | kr48.5b | kr7.0b | -kr1,754,401,584.00 | 43.1x | -27.6x | 6.9x |
| Mon, 26 Sep 2022 | kr48.9b | kr7.0b | -kr1,739,821,936.00 | 47x | -28.1x | 7x |
| Wed, 24 Aug 2022 | kr52.0b | kr6.9b | -kr1,785,898,014.00 | 58.8x | -29.1x | 7.5x |
| Fri, 22 Jul 2022 | kr50.6b | kr6.1b | -kr1,439,080,696.00 | 42.6x | -35.1x | 8.3x |
| Sun, 19 Jun 2022 | kr51.0b | kr5.9b | -kr1,509,116,648.00 | 43.4x | -33.8x | 8.6x |
| Tue, 17 May 2022 | kr48.2b | kr5.6b | -kr1,215,899,761.00 | 43.3x | -39.6x | 8.6x |
| Thu, 14 Apr 2022 | kr55.9b | kr5.5b | -kr1,336,664,342.00 | 38.8x | -41.8x | 10.1x |
| Sat, 12 Mar 2022 | kr50.1b | kr5.4b | -kr1,389,013,613.00 | 30.5x | -36.1x | 9.2x |
| Mon, 07 Feb 2022 | kr52.0b | kr5.3b | -kr1,033,431,217.00 | 91.7x | -50.3x | 9.8x |
| Wed, 05 Jan 2022 | kr57.4b | kr5.5b | -kr1,100,068,727.00 | 127.5x | -52.1x | 10.5x |
| Fri, 03 Dec 2021 | kr55.2b | kr5.5b | -kr1,097,567,682.00 | 120.8x | -50.3x | 10.1x |
| Sun, 31 Oct 2021 | kr51.6b | kr5.0b | -kr1,432,298,764.00 | 134.3x | -36.1x | 10.3x |
| Tue, 28 Sep 2021 | kr54.6b | kr4.8b | -kr1,582,510,595.00 | 166.1x | -34.5x | 11.4x |
| Thu, 26 Aug 2021 | kr55.3b | kr4.8b | -kr1,413,242,854.26 | 166.1x | -39.1x | 11.5x |
| Fri, 02 Jul 2021 | kr54.0b | kr4.8b | -kr1,412,039,942.26 | 143.4x | -38.2x | 11.3x |
Price to Earnings Ratio
-36.2x
Current Industry PE
- Investors are relatively neutral on the Swedish Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 8.1x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Revenues for these companies have grown 12% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Swedish Pharma compare with similar industries?
| SE Market | 3.49% | |
| Healthcare | 2.41% | |
| Pharma | 7.69% | |
| Pharma | 7.69% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| CAMX Camurus | kr564.00 | 13.5% +kr3.9b | 118.8% | PE72.1x | |
| CALTX Calliditas Therapeutics | kr110.80 | 3.9% +kr225.4m | -14.5% | PS4.9x | |
| IRLAB A IRLAB Therapeutics | kr13.05 | 19.2% +kr108.9m | 33.4% | PS119.2x | |
| IBT B Infant Bacterial Therapeutics | kr93.00 | 5.2% +kr62.0m | 99.1% | PS18157.1x | |
| ORX Orexo | kr19.26 | 5.6% +kr35.1m | 81.7% | PS1.1x |